COMPANY PROFILE

Oncologie

Explore full profile

Developing next-generation biologics and small molecules

Waltham, United StatesFounded 2018Biotech & Life Sciences

Valuation $250–500M Last recorded · 2019

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

At a glance

Status: Operational
Founded: 2018
Headquarters: Waltham, United States
Employees: 8
Open positions: None listed
Dealroom signal: 26.0/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Founder mafia, market maps, research and news connected to this company by Dealroom

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Jun 2019	$80M	$320M	Korea Investment Partners · Nan Fung Life Sciences Real Estate	—
SEEDOther financing	Jun 2018	$17M	$66M	Volcanics Venture · Nan Fung Life Sciences Real Estate	—

Oncologie website traffic

Latest recorded traffic for Oncologie is 0 monthly website visits, down 100% over the last three months. Oncologie's team grew 0% over the past year.

Latest monthly visits0 3-month web change-100% 1-year team growth0%

Monthly website visitsJun 2018–Jul 2020

Summary metrics are public; monthly history is available with a demoCompare with peers →

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATAtG TherapeuticsAt AtG, we develop novel classes of medicines and biomarkers to prevent cancer therapeutic resistance	L'Hospitalet de Llobregat, Spain	Operational	10	$616K	$2.5M
CGCold GenesysOncolytic immunotherapy \| CG0070 \| Cold Genesys	Santa Ana, United States	Operational
PBPersephone BiosciencesSynthetic biology company developing a platform to industrialize and scale the microbiome	San Diego, United States	Operational
ATAsgard TherapeuticsSpin-off company from Lund University focusing on developing cancer immunotherapies based on cell fate reprogramming	Lund Municipality, Sweden	Operational
PRProGeLifeDevelopment of drugs for the treatment of rare genetic aging diseases	Marseille, France	Operational
INInnocareA Chinese biopharmaceutical company that develops treatment for cancer and autoimmune diseases	Haidian, China	Operational
AUAutolusProgrammed T-cell immunotherapies for cancer and autoimmune diseases	London, United Kingdom	Operational
MPMaaT PharmaDevelops a series of microbiome-based drugs targeting mortality and comorbidities associated with blood cancer treatments	Lyon, France	Operational